Literature DB >> 2159323

Stabilization of the topoisomerase II-DNA cleavage complex by antineoplastic drugs: inhibition of enzyme-mediated DNA religation by 4'-(9-acridinylamino)methanesulfon-m-anisidide.

M J Robinson1, N Osheroff.   

Abstract

In order to elucidate the mechanism by which the intercalative antineoplastic drug 4'-(9-acridinylamino)methanesulfon-m-anisidide (m-AMSA) stabilizes the covalent topoisomerase II-DNA cleavage complex, the effect of the drug on the DNA cleavage/religation reaction of the type II enzyme from Drosophila melanogaster was examined. At a concentration of 60 microM, m-AMSA enhanced topoisomerase II mediated double-stranded DNA breakage approximately 5-fold. Drug-induced stabilization of the enzyme-DNA cleavage complex was readily reversed by the addition of EDTA or salt. When a DNA religation assay was utilized, m-AMSA was found to inhibit the topoisomerase II mediated rejoining of cleaved DNA approximately 3.5-fold. This result is similar to that previously reported for the effects of etoposide on the activity of the Drosophila enzyme [Osheroff, N. (1989) Biochemistry 28, 6157-6160]. Thus, it appears that structurally disparate classes of topoisomerase II targeted antineoplastic drugs stabilize the enzyme's DNA cleavage complex primarily by interfering with the ability of topoisomerase II to religate DNA.

Entities:  

Mesh:

Substances:

Year:  1990        PMID: 2159323     DOI: 10.1021/bi00462a012

Source DB:  PubMed          Journal:  Biochemistry        ISSN: 0006-2960            Impact factor:   3.162


  16 in total

1.  Position-specific effect of ribonucleotides on the cleavage activity of human topoisomerase II.

Authors:  Y Wang; A Thyssen; O Westergaard; A H Andersen
Journal:  Nucleic Acids Res       Date:  2000-12-15       Impact factor: 16.971

2.  Amsacrine as a topoisomerase II poison: importance of drug-DNA interactions.

Authors:  Adam C Ketron; William A Denny; David E Graves; Neil Osheroff
Journal:  Biochemistry       Date:  2012-02-10       Impact factor: 3.162

3.  Impact of the C-terminal domain of topoisomerase IIalpha on the DNA cleavage activity of the human enzyme.

Authors:  Jennifer S Dickey; Neil Osheroff
Journal:  Biochemistry       Date:  2005-08-30       Impact factor: 3.162

4.  In vivo etoposide-resistant C6 glioma cell line: significance of altered DNA topoisomerase II activity in multi-drug resistance.

Authors:  T Taki; T Ohnishi; N Arita; S Hiraga; T Hayakawa
Journal:  J Neurooncol       Date:  1998-01       Impact factor: 4.130

5.  Cell-cycle-dependent phosphorylation and activity of Chinese-hamster ovary topoisomerase II.

Authors:  D A Burden; L J Goldsmith; D M Sullivan
Journal:  Biochem J       Date:  1993-07-01       Impact factor: 3.857

Review 6.  Defining functional drug-interaction domains on topoisomerase II by exploiting mechanistic differences between drug classes.

Authors:  N Osheroff; A H Corbett; S H Elsea; M Westergaard
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

Review 7.  Novel actions of inhibitors of DNA topoisomerase II in drug-resistant tumor cells.

Authors:  W T Beck; R Kim; M Chen
Journal:  Cancer Chemother Pharmacol       Date:  1994       Impact factor: 3.333

8.  A pyrimido[1,6-a]benzimidazole that enhances DNA cleavage mediated by eukaryotic topoisomerase II: a novel class of topoisomerase II-targeted drugs with cytotoxic potential.

Authors:  A H Corbett; P Guerry; P Pflieger; N Osheroff
Journal:  Antimicrob Agents Chemother       Date:  1993-12       Impact factor: 5.191

9.  DNA topoisomerases from pathogenic fungi: targets for the discovery of antifungal drugs.

Authors:  L L Shen; J Baranowski; J Fostel; D A Montgomery; P A Lartey
Journal:  Antimicrob Agents Chemother       Date:  1992-12       Impact factor: 5.191

10.  Effects of novel fluoroquinolones on the catalytic activities of eukaryotic topoisomerase II: Influence of the C-8 fluorine group.

Authors:  M J Robinson; B A Martin; T D Gootz; P R McGuirk; N Osheroff
Journal:  Antimicrob Agents Chemother       Date:  1992-04       Impact factor: 5.191

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.